Rockville, MD — 11/13/2017 — General purpose wipes are ideal for the cleaning and the maintenance in both industrial and institutional settings. With an improving global economy and a spurt in the manufacturing activities all over the world, there is a huge demand for general purpose wipes. The main characteristics of general purpose wipes are that they are easy to use, can be easily disposed and reduce the risk of cross contamination. As the consumers presently are becoming aware of the environmental problems and solid waste generation, manufacturers are making such type of wipes that are biodegradable and can be disposed easily without having an adverse impact on the environment. One of the major drivers contributing to the increased demand of the general purpose wipes is the accelerated pace of industrial manufacturing. Also, in the year 2013, the Environmental Protection Agency of United States declared the solvent contaminated disposable wipes as non-hazardous solid waste, thereby increasing their use and making them competitive against reusable shop towels. Besides their industrial uses, general purpose wipes are also used in healthcare settings and food service industries to prevent infections and cross contaminations.
Request Free Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=183
The global general purpose wipes market is slated to touch a value of nearly US$ 1,450 Mn in the year 2022 and grow at a moderate CAGR during the assessment period.
4 Forecast Highlights on Global General Purpose Wipes Market
1- As per the forecast of Fact.MR, the anti-static wipe segment is slated to touch a value of nearly US$ 160 Mn in the year 2022. This represents a robust CAGR growth during the assessment period of 2017-2022. The anti-static wipe segment is estimated to account for more than one-tenth of the revenue share of the product type segment by the year 2017 end and is expected to gain in market share by the year 2022 end.
2- As per the forecast of Fact.MR, the paper material type segment will reach a value of nearly US$ 300 Mn in the year 2017. This represents a moderate CAGR growth during the forecast period. The paper material type segment is estimated to account for more than one-fourth of the revenue share of the material type segment in the year 2017 end and is expected to gain market share by the end of the year 2022.
3- As per the forecast of Fact.MR, the modern trade segment is slated to reach a value of nearly US$ 475 Mn in 2022. The modern trade segment is expected to gain some market value by the end of the year 2022. The largest share is contributed by the Europe region in the modern trade segment.
4- Fact.MR forecasts the wet wipes segment to grow from nearly US$ 770 Mn in 2017 to nearly US$ 960 Mn in 2022. This represents a compound annual growth rate (CAGR) of 4.5% from 2017 to 2022.
Browse Full Report with TOC- https://www.factmr.com/report/183/general-purpose-wipes-market
The report has also profiled leading players in the global market for general purpose wipes, which will remain active through 2022. These include companies such as Hengan International Group Company Limited, Sebapharma GmbH & Co. KG, Johnson & Johnson, First Quality Enterprises, Farlin Infant Product Corporation, Svenska Cellulosa Aktiebolaget SCA, Procter & Gamble, Cotton Babies Inc., Pigeon Corporation, Kimberly-Clark, Himalaya Wellness Drug Company, Unicharm and Burt's Bees.
Check Discount- https://www.factmr.com/connectus/sample?flag=D&rep_id=183
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
Latest posts by Maria Burns (see all)
- Magna Announces Fourth Quarter and 2017 Results and Raises Quarterly Cash Dividend by 20% - February 22, 2018
- Leading Token Venture Investor, Multicoin Capital Partners With Apex Token Fund for Upcoming ICO - February 22, 2018
- Novo Nordisk successfully completes the first phase 3a trial, PIONEER 1, with oral semaglutide - February 22, 2018